Rocket Pharmaceuticals (RCKT) Total Current Liabilities (2016 - 2025)
Rocket Pharmaceuticals (RCKT) has disclosed Total Current Liabilities for 10 consecutive years, with $30.2 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities fell 25.75% to $30.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.2 million through Dec 2025, down 25.75% year-over-year, with the annual reading at $30.2 million for FY2025, 25.75% down from the prior year.
- Total Current Liabilities hit $30.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $31.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $48.5 million in Q4 2023 to a low of $22.2 million in Q4 2021.
- Historically, Total Current Liabilities has averaged $33.4 million across 5 years, with a median of $33.2 million in 2023.
- Biggest five-year swings in Total Current Liabilities: soared 91.78% in 2021 and later crashed 44.26% in 2022.
- Year by year, Total Current Liabilities stood at $22.2 million in 2021, then surged by 76.7% to $39.2 million in 2022, then grew by 23.84% to $48.5 million in 2023, then fell by 16.12% to $40.7 million in 2024, then decreased by 25.75% to $30.2 million in 2025.
- Business Quant data shows Total Current Liabilities for RCKT at $30.2 million in Q4 2025, $31.2 million in Q3 2025, and $43.4 million in Q2 2025.